Abstract:OBJECTIVE:To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125. METHODS:Apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes were assessed by flow cytometry. Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20). Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor. Level of serum CA125 of the patients with ovarian cancer was assessed. RESULTS:In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05). The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05). In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances). The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01). There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009). For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009). CONCLUSIONS:(1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer. In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.

Changes and significances of VEGF and CA125 in Ovary Cancer Patients

Clinical evaluation of serum CA-125 concentrations in ovary endometriosis patients

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

[Value of Serum CA(125) Detection for Predicting Recurrence and Prognosis in Ovarian Epithelial Cancer].

The clinical significance of the serum CA125 level in ovarian cancer

[Expressions of VEGF/VEGFRs and Activation of STATs in Ovarian Carcinoma].

[Expression of Mrna Isoforms of Vascular Endothelial Growth Factor in Ovarian Carcinoma]

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer

Evaluation of Serum CA125-Tn Glycoform in Peritoneal Dissemination and Surgical Completeness of High-Grade Serous Ovarian Cancer

The Prognostic Value of the Serum CA125 Detection in Patients with Epithelial Ovarian Carcinoma

Serum Levels of Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasm

Study of Apoptosis and Fas Expression of Peritoneal Fluid and Peripheral Blood T Lymphocytes in Patients with Epithelial Ovarian Cancer and Their Relationship with CA125

Diagnostic Values in Ovarian Cancer with the Measurement of Serum Human Epididymis Secretory Protein 4 Combined with CA125 and Osteopontin

VEGF, VEGFRs Expressions and Activated STATs in Ovarian Epithelial Carcinoma

Clinical Significance of Combined Detection of HE4 and CA125 in the Serum and Tumor Tissues of Patients with Ovarian Cancer

[Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].

Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer

Evaluation of Serum CA125 in Diagnosis of Epithelial Ovarian Carcinoma

Preoperative predictive factor analysis of ovarian malignant involvement in premenopausal patients with clinical stage I endometrioid endometrial carcinoma

The Clinical Implication of Serum CA125 Assay in Endometrial Carcinoma Patients

[CA 125 Expression in Cervical and Vaginal Secretions in Women in Normal Reproductive Period].